Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
AXSM 
Axsome Therapeutics Inc (AXSM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: AXSM (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $176.84
1 Year Target Price $176.84
| 14 | Strong Buy |
| 5 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -28.98% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.91B USD | Price to earnings Ratio - | 1Y Target Price 176.84 |
Price to earnings Ratio - | 1Y Target Price 176.84 | ||
Volume (30-day avg) 19 | Beta 0.53 | 52 Weeks Range 75.56 - 139.13 | Updated Date 09/15/2025 |
52 Weeks Range 75.56 - 139.13 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.06 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -49.88% | Operating Margin (TTM) -29.87% |
Management Effectiveness
Return on Assets (TTM) -21.9% | Return on Equity (TTM) -280.69% |
Valuation
Trailing PE - | Forward PE 370.37 | Enterprise Value 5823625090 | Price to Sales(TTM) 11.94 |
Enterprise Value 5823625090 | Price to Sales(TTM) 11.94 | ||
Enterprise Value to Revenue 11.76 | Enterprise Value to EBITDA -14.81 | Shares Outstanding 49901500 | Shares Floating 41981622 |
Shares Outstanding 49901500 | Shares Floating 41981622 | ||
Percent Insiders 15.87 | Percent Institutions 77.52 |
Upturn AI SWOT
Axsome Therapeutics Inc
Company Overview
History and Background
Axsome Therapeutics, Inc. was founded in 2012 and is a biopharmaceutical company focused on developing and commercializing novel therapies for central nervous system (CNS) disorders.
Core Business Areas
- CNS Therapeutics Development: Axsome focuses on developing and commercializing innovative therapies for CNS conditions such as depression, Alzheimer's disease agitation, narcolepsy, and other neurological disorders.
Leadership and Structure
The leadership team includes Herriot Tabuteau, MD (CEO). The organizational structure comprises research and development, clinical operations, and commercial functions.
Top Products and Market Share
Key Offerings
- AUVELITY: AUVELITY is an oral NMDA receptor antagonist with multimodal activity approved for the treatment of major depressive disorder (MDD) in adults. Competitors include SSRIs, SNRIs, and other atypical antidepressants (e.g., Eli Lilly's Prozac, Cymbalta and Wellbutrin respectively).
- Sunosi: Sunosi is a dual-acting dopamine and norepinephrine reuptake inhibitor approved for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Competitors include Wakix, Xyrem, and Xywav (Jazz Pharmaceuticals).
Market Dynamics
Industry Overview
The biopharmaceutical industry focused on CNS disorders is characterized by high unmet needs, complex regulatory pathways, and significant market opportunities.
Positioning
Axsome Therapeutics is positioning itself as an innovator in CNS therapeutics by developing differentiated therapies that address unmet needs.
Total Addressable Market (TAM)
The TAM for CNS disorders is estimated in the billions of dollars. Axsome aims to capture a significant portion of this TAM with its novel therapies.
Upturn SWOT Analysis
Strengths
- Innovative pipeline
- Approved therapies
- Experienced management team
- Strong intellectual property
Weaknesses
- Reliance on key products
- Limited commercial infrastructure
- History of losses
- Dependence on regulatory approvals
Opportunities
- Expansion into new indications
- Strategic partnerships
- Geographic expansion
- Acquisition of complementary assets
Threats
- Competition from established players
- Regulatory hurdles
- Patent expirations
- Clinical trial failures
Competitors and Market Share
Key Competitors
- LLY
- JAZZ
- VRAY
- TEVA
Competitive Landscape
Axsome's advantages include novel therapies and focus on unmet needs. Disadvantages include limited commercial infrastructure and reliance on key products.
Major Acquisitions
Sunosi from Jazz Pharmaceuticals
- Year: 2022
- Acquisition Price (USD millions): 50
- Strategic Rationale: To strengthen its neurological portfolio with a commercialized product for excessive daytime sleepiness.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by clinical trial progress and regulatory approvals.
Future Projections: Future growth is projected based on sales of approved therapies and pipeline advancements. Analyst estimates vary.
Recent Initiatives: Recent initiatives include commercial launches of AUVELITY and Sunosi, as well as continued clinical development programs.
Summary
Axsome Therapeutics is a growing biopharmaceutical company with innovative therapies for CNS disorders. Its strengths lie in its pipeline and approved products, but it faces challenges related to competition and commercialization. Successful execution of its growth strategy is crucial for long-term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Company Website
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Axsome Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2015-11-19 | Founder, Chairman, CEO & President Dr. Herriot Tabuteau M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 846 | Website https://www.axsome.com |
Full time employees 846 | Website https://www.axsome.com | ||
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase III trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.